All In Biotech

Drug Trial Radar · NCT05929664

Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery

Neoadjuvant REGN2810 (Cemiplimab) or REGN2810 (Cemiplimab) Plus REGN3767 (Fianlimab) in Cutaneous Basal Cell Carcinoma of the Head and Neck

Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Suspended

Status

Suspended

Enrollment

70

Planned (sponsor's estimate)

Start

Jul 5, 2023

Primary completion

Jul 5, 2031

Study completion Jul 5, 2031

Sponsor

Lead sponsor
Thomas Jefferson UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Regeneron Pharmaceuticals
First posted
Jul 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A non-randomized two-cohort study of neoadjuvant Cemiplimab or neoadjuvant Cemiplimab plus Fianlimab (CF) in patients with basal cell carcinoma of the head and neck. Enrollment in the dual-therapy cohort will begin after completion of enrollment in the monotherapy cohort. Patients will undergo at least 2 and up to 6 infusions of immunotherapy prior to surgical resection. If patients have progression on neoadjuvant treatment, they may switch to standard of care surgical resection or hedgehog inhibitors prior to surgery. The primary endpoints are objective response rate and disease control rate. Safety and surgical benefit rate (de-escalation of surgery) with preservation of key anatomic structures are secondary endpoints. Correlative endpoints include analysis of pre and post treatment primary tumor and blood samples compared for histology, tumor genetics and immune cell composition.

Conditions

  • Locally Advanced Basal Cell Carcinoma
  • Basal Cell Carcinoma

Interventions

  • CemiplimabBiological

    Given IV

  • Computed TomographyProcedure

    Undergo CT scan

  • Biospecimen CollectionProcedure

    Undergo collection of blood samples

  • Quality-of-Life AssessmentOther

    Ancillary studies

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • BiopsyProcedure

    Undergo biopsy

  • FianlimabBiological

    Fianlimab (REGN3767) administered intravenously in combination with Cemiplimab.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: Up to 6 months post surgery (up to Day 309 +/- 3 days)
  2. Disease control rate (DCR)Time frame: Up to 6 months post surgery (up to Day 309 +/- 3 days)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • University of Miami Health System

    Miami, Florida

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • Vanderbilt University

    Nashville, Tennessee

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.